Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Risperidone (Risperdal®) is an atypical antipsychotic with high affinity for 5-hydroxytryptamine (5-HT)2A, dopamine D2 and α1- and α2-adrenergic receptors. Risperidone is now approved in the UK and the US for use in bipolar mania.
Risperidone ≤6 mg/day, as monotherapy or adjunctive therapy with first-line mood stabilisers, significantly improves moderate and severe bipolar mania and improves global functioning over 3 weeks. Improvements in Young Mania Rating Scale (YMRS) scores in double-blind trials were greater with risperidone than with placebo over 3 weeks, and similar to those with haloperidol over 3 and 12 weeks. Risperidone was reasonably well tolerated. Limited data are available on the combination of risperidone and carbamazepine. Risperidone, as monotherapy or combined therapy with lithium or valproate semisodium, is an effective treatment option in bipolar mania.
Risperidone is a benzisoxazole derivative with high in vitro affinity for 5-HT (serotonin)2A, dopamine D2 and α1- and α2-adrenergic receptors. Risperidone and its active metabolite 9-hydroxyrisperidone antagonise serotonin and dopamine. The neurotransmitter binding properties of risperidone provide the putative mechanisms for the antipsychotic and antimanic activity of risperidone and its generally improved adverse effect profile compared with older antipsychotics.
Oral risperidone is rapidly absorbed, reaching maximum plasma concentration after ≈1–2 hours, with a high bioavailability. Risperidone is largely hydroxylated by the cytochrome P450 (CYP) 2D6 enzyme to 9-hydroxyrisperidone. The elimination half-life (t1/2β) of risperidone plus 9-hydroxyrisperidone (total active moiety) is ≈20 hours. Excretion is mostly through the urine. Clearance is reduced and t1/2gb extended in elderly patients and those with renal impairment. Plasma protein binding is 90%; hepatic impairment increases unbound risperidone levels by 35%. Total active moiety plasma concentrations increase with coadministration of CYP2D6 or CYP3A4 inhibitors (e.g. fluoxetine) and decrease with CYP2D6 or CYP3A4 inducers (e.g. carbamazepine).
In 3- and 4-week double-blind trials in acute mania, risperidone at a mean modal dosage of 3.8–6 mg/day reduced mania significantly more than placebo (and similarly to haloperidol) when administered as monotherapy or adjunctive therapy, except when used as adjuvant therapy to carbamazepine. Mean baseline YMRS scores of 24.8–37.4 points decreased by 10.6–22 points with risperidone, 13.4–14.6 points with haloperidol, 12.7 points with lithium and 4.8–10.3 points with placebo, with or without mood stabilisers. When carbamazepine recipients, in whom plasma risperidone concentrations in adjuvant therapy were decreased by 40%, were included, decreases in YMRS scores in one trial were not significant versus placebo.
Remission (YMRS score ≤8 and Montgomery-Åsberg Depression Rating Scale score ≤12 points) was achieved within 3 weeks in 20% of risperidone monotherapy versus 9% of placebo recipients. Measures of illness severity, such as Clinical Global Impressions rating, improved more with risperidone than placebo; some measures (e.g. Brief Psychiatric Rating Scale scores) improved more quickly with risperidone than with haloperidol.
YMRS scores continued to improve (to ≈12 points), as did measures of patient functioning, with risperidone and haloperidol monotherapy in a subsequent 9-week double-blind trial; open-label studies reported similar results, with YMRS scores mostly <8 points after 3 months of risperidone treatment.
In addition to weight gain, common adverse events affecting >10% of recipients of risperidone, haloperidol or placebo in controlled trials were extrapyramidal symptoms (EPS), somnolence, hyperkinesia, headache, dizziness, dyspepsia, nausea and constipation. EPS were significantly more frequent with risperidone adjunctive therapy than with placebo, but the severity of symptoms was similar. Prolactin levels increased in two trials and hyperprolactinaemia, sometimes clinically relevant, occurred with risperidone.
Weight gain with risperidone was significant versus placebo, but data from single-blind and nonblind trials indicate that weight gain is generally lower than with olanzapine. Similarly, data from reviews indicates that plasma glucose is less affected by risperidone than byclozapine or olanzapine; plasma glucose was not affected by risperidone in trials in patients with mania.
- Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association, Washington DC
- Waraich, P, Goldner, EM, Somers, JM (2004) Prevalence and incidence studies of mood disorders: a systematic review of the literature. Can J Psychiatry 49: pp. 124-38
- Sachs, GS (2003) Unmet clinical needs in bipolar disorder. J Clin Psychopharmacol 23: pp. 2S-8S
- World Health Organisation. The World Health Report 2000 [online]. Available from URL: http://www.who.int/whr2001/2001 [Accessed 2004 Apr 16]
- Yatham, LN (2002) Mood stabilization and the role of antipsychotics. Int Clin Psychopharmacol 3: pp. 2S1-7S
- Stahl, SM (2003) Describing an atypical antipsychotic: receptor binding and its role in pathophysiology. Primary Care Companion J Clin Psychiatry 3: pp. 9-13
- Bhana, N, Spencer, CM (2000) Risperidone: a review of its use in the management of the behavioural and psychological symptoms of dementia. Drugs Aging 16: pp. 451-71 CrossRef
- Swainston-Harrison, T, Goa, KL (2004) Long-acting risperidone: a review of its use in schizophrenia. CNS Drugs 18: pp. 113-32 CrossRef
- Baptista, T, Kin, NM, Beaulieu, S (2002) Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 35: pp. 205-19 CrossRef
- Haddad, PM, Wieck, A (2004) Antipsychotic-induced hyperprolactinaemia. Drugs 64: pp. 2291-314 CrossRef
- Hirschfeld, RM, Keck, PE, Kramer, M (2004) Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry 161: pp. 1057-65 CrossRef
- Kapur, S, Seeman, P (2001) Does fast dissociation from the dopamine D2 receptor explain the action of atypical antispychotics? a new hypothesis. Am J Psychiatry 158: pp. 360-9 CrossRef
- Schotte, A, Janssen, PFM, Gommeren, W (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 124: pp. 57-73 CrossRef
- Snoeck, E, Peer, A, Sack, M (1995) Influence of age, renal and liver impairment of the pharmacokinetics of risperidone in man. Psychopharmacology (Berl) 122: pp. 223-9 CrossRef
- Heykants, J, Huang, M-L, Mannens, G (1994) The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry 55: pp. 13-7
- Balant-Gorgia, AE, Gex-Fabry, M, Genet, C (1999) Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: reappraisal of interindividual variability factors. Ther Drug Monit 21: pp. 105-15 CrossRef
- Bork, JA, Rogers, T, Wedlund, PJ (1999) A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. J Clin Psychiatry 60: pp. 469-76 CrossRef
- Odou, P, Levron, JC, Luyckx, M (2000) Risperidone drug monitoring: a useful clinical tool?. Clin Drug Invest 19: pp. 283-92 CrossRef
- Ravindran, A, Silverstone, P, Lacroix, D (2004) Risperidone does not affect steady-state pharmacokinetics of divalproex sodium in patients with bipolar disorder. Clin Pharmacokinet 43: pp. 733-40 CrossRef
- Janssen Pharmaceutica Products LP. Risperdal® (Risperidone) full US prescribing information 2003 Dec [online]. Available from URL: http://www.risperdal.com [Accessed 2004 Aug 16]
- Janssen-Cilag Ltd. Risperdal: Summary of Product Characteristics [online]. Available from URL: http://www.janssencilag.co.uk [Accessed 2004 Aug 2]
- Smulevich, AB, Khanna, S, Eerdekens, M (2005) Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neurop-sychopharmacol 15: pp. 75-84 CrossRef
- Segal, J, Berk, M, Brook, S (1998) Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin Neuropharmacol 21: pp. 176-80
- Khanna S, Vieta E, Lyons B, et al. Risperidone in the treatment of acute bipolar mania: a double-blind, placebo-controlled study of 290 patients. Poster presented at the 16th Annual Congress of the European College of Neurop-sychopharmacology (ECNP)2003 Sep 20-24; Prague
- Sachs, GS, Grossman, F, Ghaemi, SN (2002) Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 159: pp. 1146-54 CrossRef
- Yatham, LN, Grossman, F, Augustyns, I (2003) Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br J Psychiatry 182: pp. 141-7
- Liu T. Risperidone or clozapine combined with lithium in treatment of acute mania [abstract no. PO-7-27]. 12th World Congress of Psychiatry; 2002 Aug 24–9; Yokohama
- Baker RW, Zarate CM, Brown E, et al. A three-week comparison of olanzapine versus risperidone in the treatment of bipolar mania: improvement in manic and depressive symptoms and treatment adherence [abstract no. 15]. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17–22; San Francisco CA
- Hirschfeld RMA, Eerdekens M, Sutherland SM, et al. Risperidone monotherapy in acute bipolar mania: a nine-week extension trial in the United States [abstract no. NR723]. New Research Abstracts from the 157th Annual Meeting of the American Psychiatric Association; 2004 May 1–6, New York 2004, 272
- Bowden, CL, Myers, JE, Grossman, F (2004) Risperidone in combination with mood stabilizers: a 10-week continuation phase study in bipolar I disorder. J Clin Psychiatry 65: pp. 707-14 CrossRef
- Bahk W-M, Yoon J-S, Kim Y-H, et al. Risperidone in combination with mood stabilisers for acute mania: a multicentre, open study. Int Clin Psychopharmacol 2004; 19 299-303
- Vieta, E, Brugue, E, Goikolea, JM (2004) Acute and continuation risperidone monotherapy in mania. Hum Psychopharmacol 19: pp. 41-5 CrossRef
- Yatham, LN, Binder, C, Riccardelli, R (2003) Risperidone in acute and continuation treatment of mania. Int Clin Psychopharmacol 18: pp. 227-35 CrossRef
- Young, RC, Biggs, JT, Ziegler, VE (1978) A rating scale for mania: reliability, validity and sensitivity. Brit J Psychiat 133: pp. 429-35 CrossRef
- Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 159: pp. 1-50 CrossRef
- Newcomer, JW, Haupt, DW, Fucetola, R (2002) Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 59: pp. 337-45 CrossRef
- McIntyre, RS, Mancini, DA, Basile, VS (2003) Antipsychoticinduced weight gain: bipolar disorder and leptin. J Clin Psychopharmacol 23: pp. 323-7 CrossRef
- Knegtering, R, Castelein, S, Bous, H (2004) A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning. J Clin Psychopharmacol 24: pp. 56-61 CrossRef
- Lee, S-M, Kim, Y, Choi, N-K (2004) Weight change in ziprasidone and risperidone treatment: randomized single blind multicenter trial [abstract no. 157]. Pharmacoepidemiol Drug Saf 13: pp. S80
- David, SR, Taylor, CC, Kinon, BJ (2000) The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 22: pp. 1085-96 CrossRef
- Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27: pp. 596-601 CrossRef
- ADRAC reports on atypical antispychotic-associated diabetes. Reactions 1006: pp. 3
- McGarry, LJ, Bird, AP, Thompson, D (2003) Cost-effectiveness of atypical antipsychotics in acute bipolar mania [abstract no. PMH26]. Value Health 2003 6: pp. 352 CrossRef
- McGarry, L, Bird, AP, Thompson, D (2003) Cost-effectiveness of atypical antipsychotics for treatment of acute mania in the UK [abstract no. P.1.203]. Eur Neuropsychopharmacol 13: pp. S261 CrossRef
- Ertugrul, A, Meltzer, HY (2003) Antipsychotic drugs in bipolar disorder. Int J Neuropsychopharmacol 6: pp. 277-84 CrossRef
- Grunze, H, Kasper, S, Goodwin, G (2003) The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part II: treatment of mania. World J Biol Psychiatry 4: pp. 5-13 CrossRef
- Goodwin, GM (2003) Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. The Consensus Group of the British Association for Psychopharmacology. J Psychopharmacol (Oxf) 17: pp. 149-73
- Sachs GS, Printz DJ, Kahn DA, et al. The Expert Consensus Guideline Series: Medication treatment of bipolar disorder 2000. Postgrad Med 2000 Apr; Spec No: 1-104
- Sachs, GS (2003) Decision tree for the treatment of bipolar disorder. J Clin Psychiatry 8: pp. 35-40
- Zarate, C Jr (2000) Antipsychotic drug side effect issues in bipolar manic patients. J Clin Psychiatry 8: pp. 52-61
- Wolters Kluwer Health Inc.. Facts & Comparisons [online]. Available from URL: http://www.efactsonline.com [Accessed 2005 Feb 23]
- British National Formulary. The Pharmaceutical Press, London
Volume 19, Issue 5 , pp 429-444
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors